Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Cocrystal Pharma to related businesses based on the strength of its risk, institutional ownership, valuation, dividends, profitability, analyst recommendations and earnings.
Profitability
This table compares Cocrystal Pharma and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -320.01% | -158.73% |
| Cocrystal Pharma Competitors | -2,391.71% | -204.89% | -14.89% |
Analyst Recommendations
This is a breakdown of recent ratings for Cocrystal Pharma and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 1 | 0 | 1 | 0 | 2.00 |
| Cocrystal Pharma Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
Valuation & Earnings
This table compares Cocrystal Pharma and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cocrystal Pharma | N/A | -$8.83 million | -1.23 |
| Cocrystal Pharma Competitors | $17.31 billion | $3.17 billion | 560.54 |
Cocrystal Pharma’s competitors have higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Cocrystal Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Cocrystal Pharma’s competitors have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.
Summary
Cocrystal Pharma competitors beat Cocrystal Pharma on 10 of the 13 factors compared.
About Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
